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formed to determine economic advisability of its applying in Belarus. Methods: 
Markov model with 12-month cycle duration and 10-year time horizon has been 
constructed on the basis of a systematic review of literature, national surveillance 
data, local health services market and drugs market estimation. Four conditions 
were included: stable process, non-fatal event (cardiac infraction or unstable 
angina), surgical revascularization, death. Number of patients with stable angina 
who stayed alive and QALY till the end of the last analyzed cycle of the model has 
been used as a measure of efficiency and utility. One-sided determinate sensitiv-
ity analysis has been conducted. Incremental values have been calculated. Direct 
medical expenses have been evaluated. Value of triple GDP per capita per year (10790 
euro) has been used as threshold. Results: Research showed clinical advantage of 
treatment scheme with ivabradine as compared to “traditional therapy” concern-
ing the amount of patients who stayed alive by the end of the last cycle of model 
(7275 vs. 6421 persons in total population and 8136 vs 6993 in patients with heart 
rate > 70 pbm) and QALY number (77635 vs. 69253 in total population and 84138 vs. 
73031 in patients with heart rate > 70 pbm years). The sensitivity analysis showed 
that in 9.09% of cases ivabradine was the prevailing technology, in 90.91% the cost 
per QALY did not exceed the threshold. The average counted incremental cost per 
QALY was 3836 Euro. ConClusions: The analysis showed the pharmacoeconomic 
acceptability of ivabradine use by patients with stable angina with left ventricular 
systolic disfunction and heart rate ≥ 70 bpm at prescription of the medication in 
optimal dosage which ensures minimal market value of the medication.
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objeCtives: Aortic valve replacement (AVR) is the most common heart valve opera-
tion, accounting for a conspicuous part of all valve surgery performed in the elderly. 
Prolonged aortic cross-clamping times are an independent risk factor for worse out-
comes. Perceval S is a new aortic valve which is implanted without need for sutur-
ing and a collapsed profile, thus allowing a significant reduction of cross-clamping 
times. Methods: A patient-level simulation model fully coded in WinBugs was 
updated and extended to predict lifetime effectiveness and costs of concomitant 
AVR procedures associated with this new valve in France and UK, as compared to 
traditional valve implants, from the cost perspective of the third party payer. Two price 
scenarios were evaluated, one in which the sutureless valve is sold at the double, and 
one at the triple price of its comparator. Unit costs and health state-specific utilities 
were retrieved from official and literature sources. Future costs and outcomes are 
discounted at a yearly 3.5% rate. Uncertainty is evaluated through the incorporated 
probabilistic sensitivity analysis and deterministic threshold analyses. Results: The 
model predicts that on average the use of the Perceval S valve instead of traditional 
sutured valves would yield incremental 0.21 LYs (0.16 QALYs) per patient, with an 
associated saving of about 5,100 € and 4,400 £ in France and UK, respectively, in 
the first scenario, and of 2,600 € and 1,900 £, in the second. Deterministic threshold 
analysis indicates that the sutureless valve would remain averagely dominant as long 
as its price does not exceed 4.1 and 3.8 times that of the traditional valve, in France 
and UK, respectively. ConClusions: The sutureless valve offers the opportunity to 
improve outcomes in concomitant AVR at a reduced cost to the third party payers.
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objeCtives: Health status plays an important role in individuals’ labour supply 
decision. Chronic diseases, such as cancer, diabetes mellitus, cardiovascular disease, 
mental illness and disabilities are reported to have strongest effect on individual 
transitions on the labour market. Among them, cardiovascular disease (CVD), in addi-
tion to being the leading cause of death, is likely to affect individuals’ employment 
decision. The aim of this study is to investigate the impact of clinically diagnosed car-
diovascular disease on labour supply, taking account of the observed and unobserved 
factors that influence the risk of cardiovascular disease and labour force participa-
tion. Methods: Study subjects were randomly selected from Gazi University general 
internal medicine outpatient clinic. Demographic, health and employment status 
data have been compiled for five hundred and fifteen study subjects who applied to 
the clinic between December 2012 and February 2013. The bivariate probit method 
has been utilized to investigate the impact of incidence of cardiovascular disease on 
employment status. Results: Empirical results indicate that cardiovascular disease 
have a strong negative impact on labour market outcomes, particularly for men, and 
that education level, gender, hypertension have significant indirect effects on labour 
force participation. Analysis results suggest that there is a correlation between the 
labour force participation and the incidence of cardiovascular disease, revealing that 
single equation models might be misspecified. ConClusions: As cardiovascular dis-
ease has a significant negative impact on employment status, public health programs 
need to address this issue and provide treatment strategies and prevention efforts to 
alleviate the destructive impact on societal productivity.
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objeCtives: To define hospital and post discharge-related resource use for patients 
undergoing Transcatheter Aortic Valve Implantation (TAVI) and conventional Aortic 
Valve Replacement (AVR) surgery within a single UK hospital. Methods: A local 
A Markov model was developed to predict the occurrence of myocardial infarction, 
stroke, coronary revascularization and death. The model considers a lifetime horizon 
and a 3.5% discount rate. Clinical inputs were derived from the JUPITER trial and 
from a cohort of the MESA study fulfilling JUPITER inclusion criteria. Event costs 
were obtained from the literature. Rosuvastatin 20mg cost incorporates a discount to 
reflect the introduction of generics within a maximum of 5 years. Results: Coronary 
calcium score determination and subsequent primary prevention in individuals 
with a score exceeding 100 dominates no treatment. Implementing primary preven-
tion in those patients with positive score, and not just those with score above 100, 
implies a willingness to pay around 40,000€ per QALY. Finally, primary prevention in 
all individuals is not cost-effective when compared to primary prevention in those 
with positive calcium score as it is associated with a cost per QALY of more than 
600,000€ . ConClusions: Determination of coronary calcium score is cost-effective 
as it allows to identify those patients that will benefit most from primary preven-
tion. Primary prevention in patients with calcium score greater than 100 should be 
implemented. The implementation of this strategy in other patients with positive 
calcium score depends on the willingness to pay for a QALY.
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objeCtives: Aortic valve replacement (AVR) is the most common heart valve 
operation, accounting for a conspicuous part of all valve surgery performed in 
the elderly. Prolonged aortic cross-clamping times are an independent risk factor. 
Perceval S is a new aortic valve which is implanted without need for suturing and a 
collapsed profile, thus allowing a significant reduction of cross-clamping times and 
to expand the pool of patients operable with mini-invasive aortic valve replacement 
(MiAVR) among isolated AVR candidates. Aim of this simulation study was to predict 
costs and outcomes of isolated AVR procedures associated with this new valve in 
Germany, as compared to traditional valve implants, from the cost perspective of 
the third party payer. Methods: A previously published probabilistic, patient-level 
simulation model fully coded in WinBugs was updated with new clinical data and 
the evaluation extended to evaluate lifetime cost-effectiveness from the perspective 
of the third party payer. Unit costs and health state-specific utilities were retrieved 
from official and literature sources; the price of the sutureless valve is hypothesised 
twice as much as for traditional valves. Future costs and outcomes are discounted 
at a yearly 3.5% rate. Results: The model predicts that on average the use of the 
Perceval S in MiAVR instead of traditional sutured valves in full sternotomy among 
isolated AVR candidates, would yield incremental 0.29 LYs (0.20 QALYs) per patient, 
with an associated saving around 3,500 € , thus representing a dominant option 
when compared to traditional surgical AVRs. In concomitant procedures, on aver-
age the use of the Perceval S valve instead of traditional sutured valves is expected 
to yield incremental 0.21 LYs (0.16 QALYs) per patient, with an associated saving of 
over 4,400 € , also representing a dominant alternative. ConClusions: Sutureless 
valves may improve outcomes in AVR at a reduced cost to the third party payers.
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objeCtives: To conduct a systematic review of cost-effectiveness studies of newer 
oral anticoagulants for stroke prevention in atrial fibrillation versus warfarin and 
understand its implications for policy and for further research. Methods: We 
searched DARE, Cochrane, NICE, Tufts, NHS EED, Science Direct and PubMed through 
May 2013 to identify studies of oral anticoagulants dabigatran, rivaroxaban and 
apixaban versus warfarin for stroke prevention in non-valvular atrial fibrillation 
in patients at a moderate-to-high risk of stroke initiating anticoagulation for/near 
lifetime using either a societal or health care perspective. A separate analysis was 
performed for ISPOR abstracts. Results: Ten studies were identified, most based 
on one randomized trial per therapy, 3 reported an ICER above commonly accepted 
WTP levels. ICERs ranged from $9,099–$86,000 for dabigatran and $3,190–$55,757 for 
rivaroxaban. Apixaban was found to be cost-effective $11,400–$24,312. Upon PSA, 
dabigatran was cost-effective 40% to 98%, apixaban 44.1% to 60%, and rivaroxaban 
2.1% to 80% of the time, for the lowest reported WTP. Variations in ICERs occurred 
between studies that used the same efficacy data. Key variables influencing vari-
ations include differences in costs; assumptions for INR monitoring and utiliza-
tion of health care resources; and the probabilities of adverse event. Effectiveness, 
compliance, adverse events and INR management were derived from clinical tri-
als. Additional data from recent abstracts reported similar trends. ConClusions: 
For this indication, novel agents seem to be cost-effective alternatives to warfarin, 
despite variations across countries. However, cost-effectiveness may depend on: 
prices of medicines in each country; the proportion of actual patients’ time within 
the INR therapeutic range; and the actual real-world effectiveness, safety, and utili-
zation of these therapies. More head-to-head RCTs and pragmatic trials are required. 
Future cost-effectiveness studies of these new therapies should be periodically 
repeated during the lifecycle of medicines under real-world utilization and should 
also incorporate budget impact analysis.
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objeCtives: Cost-effectiveness and cost-utility analysis of ivabradine use in 
patients with stable angina with left ventricular systolic dysfunction has been per-
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objeCtives: Hypertension is a common chronic disease and risk factor for many 
other conditions. Despite effective treatments, few patients achieve recommended 
blood pressure targets. Among the variables related with poor antihypertensive 
outcomes, patient adherence appears to be especially influential. Adherence 
assessment should fit seamlessly into the clinical encounter, which requires sim-
ple methods. We evaluated whether adherence assessments through a single-item 
query and a visual analogue scale (VAS) are independent predictors of controlled 
systolic (SBP), diastolic (DBP), and combined systolic/diastolic (SBP/DBP) blood pres-
sure (BP). Methods: Pooled analysis of 17,516 patients treated with valsartan as 
second-line therapy from seven Belgian studies. Adherence was assessed at baseline 
and 90 days using two methods: a single query derived from the Basel Assessment 
of Adherence Scale (“Do you recall not having taken your medication sometime in 
the past four weeks?”) and a physician-rated VAS (0-100 range). Logistic regression 
was used to model BP control as a function of these two measures. Controlled 
BP was defined as < 140mm/90mmHg (< 130/80mmHg for diabetics). Results: BP 
control rates at 90 days were 39.3% for SBP, 59.4% for DBP, and 33.8% for SBP/DBP. 
79% of patients identified as adherent under the single query reached BP control, 
with odds ratios of 0.66 (95%CI= 0.62-0.71, p< 0.001) for SBP, 0.68 (95%CI= 0.63-0.73, 
p< 0.001) for DBP, and 0.64 (95%CI= 0.59-0.70, p< 0.001) for SBP/DBP. Of those patients 
with a physician-rated VAS adherence score of 80 or more, 81% reached BP control, 
with odds ratios of 0.93 (95%CI= 0.86-1.00, p< 0.001) for SBP, 0.79 (95%CI= 0.73-0.85, 
p< 0.001) for DBP, and 0.91 (95%CI= 0.84-0.99, p< 0.001) for SBP/DBP. ConClusions: 
The two simple methods of measuring adherence, the single query and VAS, are 
independent predictors of blood pressure control. These measures can be integrated 
seamlessly into routine clinical practice. These findings must be validated in other 
health conditions and therapeutic areas.
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objeCtives: Warfarin is an oral anticoagulant used for the prevention of throm-
bosis, and many adjustments are needed to achieve a therapeutic INR. The dose 
of warfarin is important to establish an association between clinical and safety 
outcomes and the exposure. To evaluate the validity of the weekly dose of warfarin 
as reported by the patient compared to the weekly prescribed dose. Methods: 
This study was based on an ongoing prospective cohort of new warfarin-users to 
assess the genetic and clinical risks associated with the effectiveness and safety 
of warfarin. Demographic and clinical data were collected from 219 patients who 
began the treatment between May 1st, 2010 and Oct. 31st, 2011 at the Montreal 
Heart Institute. They were followed-up each three months for a year. The primary 
outcome is the concordance between the reported and prescribed weekly dose of 
warfarin. The secondary outcome is the difference between the means of reported 
and prescribed warfarin weekly doses. A t-test and a Pearson correlation are used for 
the secondary outcome and a generalized mixed linear model with repeated meas-
ures is used for the primary outcome. Results: Patients had a mean age of 67.7, 
58.9% were men and 70.3% had atrial fibrillation. No significant difference between 
the means of reported and prescribed warfarin weekly dose (Pearson coefficient = 
0.969). However, we observed that the correlation was weak at 3 months for patients 
in the low dose group and in the high dose group (Pearson coefficient = 0.806 and 
0.829, respectively). Mixed linear model analysis detected no association between 
the covariates and the concordance. ConClusions: This study demonstrates that 
the weekly reported dose correlates well with the prescribed dose patients in a 
prospective cohort study. Furthermore, the effect was similar whether measured 
in new-onset users of warfarin and up to 12 months of use.
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objeCtives: Adherence to statin therapy is important for an effective reduction 
in cardiovascular events. We aimed to assess the effect of the occurrence of a first 
cardiovascular event on adherence rates in type 2 diabetes patients using a matched 
cohort design. Methods: A matched cohort study was performed within the IADB.
nl pharmacy database among type 2 diabetes patients, who initiated statin treat-
ment for primary prevention. Index patients experienced a first event (index date) 
after initiation whereas reference patients did not. Index and reference patients 
were matched on gender, age at statin initiation, statin initiation date, adherence 
level before the index date and follow-up period. Adherence was measured as per-
centages of days covered and classified into: non-adherent, partial-adherent or 
full-adherent. Adherence rates were measured from statin initiation until the index 
date, and from the index date until end of follow-up, for reference patients in both 
cases the same follow-up period was used. Mean adherence rates between index 
and reference before and after were compared by the use of an independent samples 
service evaluation of patients undergoing TAVI or AVR between January 2011 and 
May 2012 captured data until 6-months post-procedure, collected from hospital 
records and via a General Practitioner questionnaire. The main endpoints were 
mortality, hospital length of stay (LoS), discharge destination, readmission and 
post-discharge resource use. Subgroup analyses were performed for AVR patients 
aged ≥ 80 (AVR≥ 80) and with Euroscore of ≥ 10 (AVR≥ 10). Results: Results given as 
means (standard deviation) for TAVI (n= 51), AVR (n= 188), AVR≥ 80 (n= 48) and AVR≥ 10 
(n= 47) respectively, unless otherwise stated. Age in years was 83 (3.06), 71 (13.11), 84 
(2.72), 79 (7.12), Logistic Euroscore1 was 24.74 (11.90), 8.07 (6.44), 12.01 (6.04), 16.45 
(6.58) and post-operative LoS in days was 11.51 (11.16), 10.88 (10.82), 14.31 (16.66), 
15.19 (17.67). For patients discharged alive, 0 of 48 (0%), 13 of 180 (7%), 6 of 46 (13%) 
and 4 of 44 (9%), had an unplanned cardiac-related readmission within 30-days of 
discharge. Time to readmission was 74.6 (52.9), 31.1 (37.2), 15.4 (10.5) and 16.7 (12.8) 
days. ConClusions: Despite TAVI being performed in an older, higher risk popula-
tion the LoS is similar to AVR. Most strikingly there were no cardiac-related readmis-
sions within 30-days for TAVI and time to first readmission was significantly longer. 
This evaluation suggests that TAVI is clinically appropriate and provides economic 
advantages in both the hospital and post discharge setting in this high risk group. 
Many patients undergoing TAVI are considered unfit for surgery and hence TAVI 
offers a treatment that delivers similar results to traditional AVR surgery without 
the high risk associated with surgery.
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objeCtives: To examine patients’ stated preferences for persisting with medications 
using a discrete choice experiment (DCE) and to explore the relationship with clinical, 
demographic and psycho-social variables. Methods: A 4-attribute DCE (mild side-
effects, potentially life-threatening but rare side-effects, dose frequency, treatment 
benefits) with 3-levels identified from literature and expert opinion was developed 
using a fractional factorial design. Scenarios were folded into nine forced binary 
choices: Which medicine would you be most likely to continue taking? The survey was 
translated, piloted and approved for eleven European countries. Target sample was 
100≤ n≤ 323 patients prescribed anti-hypertensives per country, recruited by posters 
in community pharmacies or general practices. Results were analysed in STATA using 
a random effects logit model. Results: A total of 2856 patients from Austria (n= 323), 
Belgium (n= 180), England (n= 323), Germany (n= 265), Greece (n= 289), Hungary (n= 323), 
The Netherlands (n= 237), Poland (n= 323) and Wales (n= 323) completed the online 
questionnaire. All four attributes influenced persistence with treatment (p< 0.01). 
Patients were willing to forego chance of improvements in treatment benefits (%) 
in order to improve other attributes: -36.10% (95% CI: -41.24 to -32.94) for a very rare 
risk of life-threatening side-effects; -18.66% (95% CI: -21.51 to -16.67) for once daily 
dose frequency; -0.74% (95% CI: -0.85 to -0.67) to reduce the risk of mild ADR by 1%. 
Likelihood ratio tests showed that models controlling for clinical, demographic and 
psycho-social variables were significantly different from the base-case. There was 
limited evidence that self-reported adherence influenced stated preferences to per-
sist. ConClusions: Patients were willing to trade potential benefits, harms, and 
convenience in responding that they would persist with treatment. Clinical, demo-
graphic and psycho-social factors influence the extent of the trade-offs between 
these attributes. Persistence may therefore be enhanced directly, through selection 
of medicines meeting preferred levels of attributes, or indirectly through targeting 
modifiable psycho-social factors that affect trade-off choices.
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objeCtives: With the recognition that adherence is commonly imperfect, even with 
once daily regimen, ‘forgiveness’ is becoming acknowledged as an important char-
acteristic in predicting real-world effectiveness. Forgiveness is typically reported 
as a group average value, ignoring person-to-person variability. Here we illustrate 
an alternative way of estimating and presenting information on drug forgiveness 
which allows the estimation of the combined effect of imperfect adherence and 
variable forgiveness. Methods: Adherence data from 4783 patients with hyper-
tension were used in these simulations. A projected dosing history over 365 days 
was obtained from each of these individual adherence profiles. Longitudinal clinic 
systolic blood pressure (SBP) collected from 4879 patients after drug withdrawal 
were analysed using non linear mixed effect models, allowing the estimation of the 
between-patient variability in the loss of effect (the ‘offset’). Projected SBP profiles 
were obtained by combining each dosing history with 100 offset curves randomly 
sampled from the variance-covariance matrix estimated in the previous step. 
Re-samplings were performed in the resulting dataset using two adherence distri-
butions described in the literature to estimate the proportion of time patients who 
achieved the maximal effect on SBP over a treatment period of 365 days. Results: 
In the first population, 90% of the patients achieved the maximal effect during 95% 
of the time, whereas, in the population presenting a lower adherence, about 80 % 
maintained the maximal effect during 95% of the time. ConClusions: The impact 
imperfect adherence on response is mitigated by drug forgiveness. This methodol-
ogy reveals the person-to-person variability in clinical effectiveness which is hidden 
when forgiveness is considered as a group-average quantity, and shows that the 
agent studied provides a reliable clinical effectiveness despite imperfect adherence. 
Ultimately, this approach could be used to compare drugs with different levels of 
forgiveness and/or regimens in the presence of non-adherence.
